Secondary cost-effectiveness analysis of the EDGE clinic-randomised trial, modelling 100,000 primary care participants: in-clinic engagement dominated mailed invitations for risk assessment, but mailed invitations yielded more genetic testing (ICER $152 per person tested).
RCT
Devine et al. Cost-effectiveness of primary care-based risk assessment and hereditary cancer genetic testing